![A moment that changed me: the chance to use new life-saving cancer drugs | Breast cancer | The Guardian A moment that changed me: the chance to use new life-saving cancer drugs | Breast cancer | The Guardian](https://i.guim.co.uk/img/media/5b7bc99bb218f15e48616bf20cf008492864297e/0_111_2521_1512/master/2521.jpg?width=700&quality=85&auto=format&fit=max&s=e47bca443a28cfdc0450d4582b72f83d)
A moment that changed me: the chance to use new life-saving cancer drugs | Breast cancer | The Guardian
![Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00284-y/MediaObjects/41523_2021_284_Fig1_HTML.png)
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
![6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/e961d20e-ceaa-45ca-9a0e-9dcf5ad06ffe/gr1.gif)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet
![Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study - The Lancet Oncology Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/2a1b9b93-6ba5-40e5-b8fd-7c109618b77b/gr1.jpg)